Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01204
|
|||||
| Drug Name |
Norfloxacin
|
|||||
| Synonyms |
1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid; AM 0715; AM 715; AM-0715; AM-715; AM0715; Apo-Norflox (TN); Baccidal; Barazan; Chibroxin; Chibroxin (TN); Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; Fulgram; Insensye (TN); Lexinor; MK 0366; MK 366; MK-0366; MK-366; MK0366; MK366; Merck Brand of Norfloxacin; NFLX; Norflo; Norflohexal (TN); Norfloxacin (JP15/USP/INN); Norfloxacin Merck Brand; Norfloxacin [USAN:BAN:INN:JAN]; Norfloxacine; Norfloxacine [INN-French]; Norfloxacino; Norfloxacino [INN-Spanish]; Norfloxacinum; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin; Noroxin (TN); Nufloxib (TN); Roxin (TN); Sebercim; Utin (TN); Utinor (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Urinary tract infections [ICD11:GC08] | Approved | [1] | |||
| Gynecological infections [ICD11:GA6Z] | Approved | [1] | ||||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H18FN3O3
|
|||||
| Canonical SMILES |
CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
|
|||||
| InChI |
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
|
|||||
| InChIKey |
OGJPXUAPXNRGGI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 70458-96-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 319.33 | Topological Polar Surface Area | 72.9 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
-1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321598
,11112831
,11335259
,11360498
,11363911
,11366473
,11369035
,11371707
,11374005
,11377197
,11461470
,11466249
,11467369
,11484909
,11485918
,11488833
,11490340
,11492268
,11494831
,12013332
,14715876
,14874649
,26611845
,26680206
,26746929
,26746930
,29223630
,3205552
,46508634
,4712110
,47440088
,47440089
,47440090
,47515159
,47736303
,47736304
,47810598
,47959570
,47959571
,48034947
,49698389
,50042536
,50100528
,597742
,7847277
,7980171
,8149451
,8152796
,855614
,8912
|
|||||
| ChEBI ID |
CHEBI:100246
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| References | ||||||
| 1 | Norfloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5. | |||||
| 3 | Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94. | |||||
| 4 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.